Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg)
Authors:
- 1 August 2000
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 43 (2) , 403-408
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Beneficial effect of granulocyte–colony stimulating factor in scleromyxoedema associated with severe idiopathic neutropeniaBritish Journal of Dermatology, 1996
- Remission of scleromyxoedema following treatment with extracorporeal photopheresisBritish Journal of Dermatology, 1996
- ScleromyxedemaJournal of the American Academy of Dermatology, 1995
- Requirements for safety and quality of intravenous immunoglobulin G preparations.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis)Journal of the American Academy of Dermatology, 1993
- RELIABILITY OF SKIN INVOLVEMENT MEASURES IN SCLERODERMARheumatology, 1992
- Extracorporeal photochemotherapy: A potentially useful treatment for scleromyxedemaJournal of the American Academy of Dermatology, 1991
- Scleromyxedema: Therapeutic response to isotretinoin in three patientsJournal of the American Academy of Dermatology, 1988
- Scleromyxoedema—successful treatment with plasma exchange and immunosuppressionBritish Journal of Dermatology, 1987
- Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids1a,b,c,dJournal of the American Chemical Society, 1946